Carlsmed, Inc. is a medical technology company specializing in the development of AI-enabled, personalized solutions for spine surgery. The company focuses on the treatment of complex adult spinal deformities, leveraging a proprietary surgical platform that integrates clinical intelligence, advanced image recognition, and 3D printing technologies. Its flagship product, aprevo®, enables surgeons to generate patient-specific surgical plans and devices that are tailored to each individual's anatomy and diagnosis. Carlsmed’s innovations aim to improve surgical outcomes, enhance the standard of care, and reduce overall healthcare costs for spinal procedures. The company’s products have received FDA Breakthrough Device Designation and are FDA-cleared, highlighting their technological significance and regulatory recognition. Founded in 2018 and headquartered in Carlsbad, California, Carlsmed plays a transformative role in the healthcare sector, particularly within medical devices and biotechnology. Its entry to public markets underscores its growing importance in advancing the capabilities of spine surgery through technology-driven, personalized patient care initiatives.